ArticleJournal of animal science and biotechnology2026
Improvement of chicken genome editing efficiency in vitro using ribonucleoprotein-mediated CRISPR/Cas9 delivery.
Article in Journal of animal science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLimitations in genome editing of avian species, including chicken, due to the inaccessibility of one-cell zygotes, have led to the manipulation of primordial germ cells (PGCs) as the primary approach for generating genetically engineered birds. Although plasmid-mediated delivery of clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) has been widely used, it has several limitations, including delayed nuclease activation, increased off-target effects, cytotoxicity, and the inability to apply in vivo selection strategies. Collectively, these limitations highlight the need to develop strategies that achieve high on-target activity at the initial editing step.
resultsIn this study, we compared plasmid- and ribonucleoprotein (RNP)-mediated CRISPR/Cas9 delivery in Leghorn male hepatoma (LMH) cells and in PGCs targeting three loci: deleted in azoospermia like (DAZL), chicken vasa homologue (CVH), and stimulated by retinoic acid 8 (STRA8). RNP delivery showed comparable or higher cell viability and editing efficiency than plasmid delivery in both cell types. Insertion/deletion (indel) profiling revealed broader and more diverse mutation patterns with RNPs, consistent with a shift in repair pathway engagement toward microhomology-mediated end joining (MMEJ), which favors larger deletions. Off-target analysis further showed substantially reduced off-target editing and high specificity with RNP delivery.
conclusionsTogether, these findings demonstrate that RNP delivery improves efficiency, reduces cytotoxicity, and improves precision, providing a more reliable platform for chicken genetic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.